Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Low circulating concentrations of citrulline and FGF19 predict chronic cholestasis and poor survival in adult patients with chronic intestinal failure: development of a Model for End-Stage Intestinal Failure (MESIF risk score)

KVK. Koelfat, A. Huijbers, FG. Schaap, SMJ. van Kuijk, M. Lenicek, MR. Soeters, GJA. Wanten, SWM. Olde Damink,

. 2019 ; 109 (6) : 1620-1629. [pub] 20190601

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006378

BACKGROUND: Patients with chronic intestinal failure (CIF) often develop cholestatic liver injury, which may lead to liver failure and need for organ transplantation. OBJECTIVES: The aim of this study was to investigate whether citrulline (CIT) and the enterokine fibroblast growth factor 19 (FGF19) are associated with chronic cholestasis and survival in adult CIF patients, and to develop a risk score to predict their survival. METHODS: We studied 135 adult CIF patients on intravenous supplementation (>3 mo). Associations of plasma CIT and FGF19 with chronic cholestasis and survival were estimated by logistic and Cox regression models. A predictive risk score was developed and validated internally. RESULTS: Patients with chronic cholestasis (17%) had a reduced 5-y survival rate compared with patients without chronic cholestasis (38% and 62%, respectively). In multivariable analysis, low FGF19, low CIT, and female sex were associated with chronic cholestasis. Patients with low rather than high CIT or FGF19 also had reduced 5-y survival rates (29% compared with 69%; 54% compared with 66%, respectively). Risk factors identified in multivariable analysis of survival were low FGF19 (HR: 3.4), low CIT (HR: 3.3), and number of intravenous infusions per week (HR: 1.4). These 3 predictors were incorporated in a risk model of survival termed Model for End-Stage Intestinal Failure (MESIF) (C-statistic 0.78). The 5-y survival rates for patients with MESIF scores of 0 to <20 (n = 47), 20-40 (n = 75), and >40 (n = 13) were 80%, 58%, and 14%, respectively. CONCLUSIONS: CIT and FGF19 predict chronic cholestasis and survival in this cohort of adult CIF patients, and the derived MESIF score is associated with their survival. Pending external validation, the MESIF score may help to identify patients for closer clinical monitoring or earlier referral to intestinal transplantation centers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006378
003      
CZ-PrNML
005      
20200528085543.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ajcn/nqz036 $2 doi
035    __
$a (PubMed)31075790
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Koelfat, Kiran V K $u Department of Surgery, Maastricht, Netherlands. NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands.
245    10
$a Low circulating concentrations of citrulline and FGF19 predict chronic cholestasis and poor survival in adult patients with chronic intestinal failure: development of a Model for End-Stage Intestinal Failure (MESIF risk score) / $c KVK. Koelfat, A. Huijbers, FG. Schaap, SMJ. van Kuijk, M. Lenicek, MR. Soeters, GJA. Wanten, SWM. Olde Damink,
520    9_
$a BACKGROUND: Patients with chronic intestinal failure (CIF) often develop cholestatic liver injury, which may lead to liver failure and need for organ transplantation. OBJECTIVES: The aim of this study was to investigate whether citrulline (CIT) and the enterokine fibroblast growth factor 19 (FGF19) are associated with chronic cholestasis and survival in adult CIF patients, and to develop a risk score to predict their survival. METHODS: We studied 135 adult CIF patients on intravenous supplementation (>3 mo). Associations of plasma CIT and FGF19 with chronic cholestasis and survival were estimated by logistic and Cox regression models. A predictive risk score was developed and validated internally. RESULTS: Patients with chronic cholestasis (17%) had a reduced 5-y survival rate compared with patients without chronic cholestasis (38% and 62%, respectively). In multivariable analysis, low FGF19, low CIT, and female sex were associated with chronic cholestasis. Patients with low rather than high CIT or FGF19 also had reduced 5-y survival rates (29% compared with 69%; 54% compared with 66%, respectively). Risk factors identified in multivariable analysis of survival were low FGF19 (HR: 3.4), low CIT (HR: 3.3), and number of intravenous infusions per week (HR: 1.4). These 3 predictors were incorporated in a risk model of survival termed Model for End-Stage Intestinal Failure (MESIF) (C-statistic 0.78). The 5-y survival rates for patients with MESIF scores of 0 to <20 (n = 47), 20-40 (n = 75), and >40 (n = 13) were 80%, 58%, and 14%, respectively. CONCLUSIONS: CIT and FGF19 predict chronic cholestasis and survival in this cohort of adult CIF patients, and the derived MESIF score is associated with their survival. Pending external validation, the MESIF score may help to identify patients for closer clinical monitoring or earlier referral to intestinal transplantation centers.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a cholestáza $x krev $x etiologie $x mortalita $7 D002779
650    _2
$a chronická nemoc $x mortalita $7 D002908
650    _2
$a citrulin $x krev $7 D002956
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblastové růstové faktory $x krev $7 D005346
650    _2
$a lidé $7 D006801
650    _2
$a nemoci střev $x komplikace $7 D007410
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Huijbers, Angelique $u Department of Gastroenterology & Hepatology, Radboud University Medical Center, Nijmegen, Netherlands.
700    1_
$a Schaap, Frank G $u Department of Surgery, Maastricht, Netherlands. NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands. Department of General, Visceral and Transplantation Surgery, RWTH University Hospital Aachen, Aachen, Germany.
700    1_
$a van Kuijk, Sander M J $u Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, Netherlands.
700    1_
$a Lenicek, Martin $u Department of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Soeters, Maarten R $u Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, location AMC, Amsterdam, Netherlands.
700    1_
$a Wanten, Geert J A $u Department of Gastroenterology & Hepatology, Radboud University Medical Center, Nijmegen, Netherlands.
700    1_
$a Olde Damink, Steven W M $u Department of Surgery, Maastricht, Netherlands. NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands. Department of General, Visceral and Transplantation Surgery, RWTH University Hospital Aachen, Aachen, Germany.
773    0_
$w MED00000237 $t The American journal of clinical nutrition $x 1938-3207 $g Roč. 109, č. 6 (2019), s. 1620-1629
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31075790 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200528085540 $b ABA008
999    __
$a ok $b bmc $g 1525236 $s 1096434
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 109 $c 6 $d 1620-1629 $e 20190601 $i 1938-3207 $m The American journal of clinical nutrition $n Am J Clin Nutr $x MED00000237
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace